Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases-Reference-Cited by-同舟云学术

Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases

Published:2015-02 Issue:2 Volume:65 Page:257-263
ISSN:0194-911X
Container-title:Hypertension
language:en
Short-container-title:Hypertension

Author:

Bauersachs Johann¹,Jaisser Frédéric¹,Toto Robert¹

Affiliation:

1. From the Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany (J.B.); Centre de Recherche des Cordeliers, Inserm U1138, Université Pierre et Marie Curie, Paris, France (F.J.); and Department of Internal Medicine, Division of Nephrology, University of Texas Southwestern Medical Center, Dallas (R.T.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.114.04488

Reference68 articles.

1. Cardiorenal Syndrome

2. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms

3. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease

4. Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives

5. Aldosterone, mineralocorticoid receptor, and heart failure

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study;Metabolism Open;2024-12

2. Therapeutic approaches and novel antifibrotic agents in renal fibrosis: A comprehensive review;Journal of Biochemical and Molecular Toxicology;2024-08

3. Decoding the role of aldosterone in glycation-induced diabetic complications;Biochemical and Biophysical Research Communications;2024-08

4. The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease;Diabetes, Obesity and Metabolism;2024-07-18

5. New ways of mitigating aldosterone in cardiorenal disease;European Heart Journal - Cardiovascular Pharmacotherapy;2024-07-10